tirzepatide hfpef trial In pts wiht and obesity, (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT https://t.co/8ZHm4gySiL Tirzepatide Benefits in Obesity-Related HFpEF

If your injections consistently hurt, your technique needs adjustment, not your pain tolerance

Excess weight is linked to risks such as: Cardiovascular disease Hypertension Certain cancers Tirzepatide improves satiety , reduces calorie intake , and enhances fat metabolism , leading to meaningful weight loss

You may be a good candidate if you: Have a BMI of 30 or higher, or 27 or higher with weight-related health concerns such as high blood pressure, insulin resistance, or prediabetes

Antonio Martorell ha recibido honorarios y/o viajes subvenciones y/o ha actuado como miembro del consejo asesor de Novartis, Abbvie, Janssen Cilag, UCB, Lilly, LEO Pharma, LOreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squibb y Amgen